Shreeram Aradhye - Dec 15, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Role: EVP & Chief Medical Officer
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Stock symbol: DRNA
Transactions as of: Dec 15, 2021
Transactions value $: -$31,696
Form type: 4
Date filed: 12/17/2021, 03:17 PM
Previous filing: Sep 17, 2021
Next filing: Dec 29, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise		+2.84K	+57.09%		7.81K	Dec 15, 2021	Direct	F1
transaction	DRNA	Common Stock	Tax liability	-$31.7K	-833	-10.67%	$38.05	6.97K	Dec 15, 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Restricted Stock Units	Options Exercise	$0	-2.84K	-25%	$0.00	8.51K	Dec 15, 2021	Common Stock	2.84K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
F2	Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
F3	The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.